Ibrutinib improves diffuse large B-cell lymphoma survival - NCI
JCI Insight - Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations
B-cell receptor signaling in diffuse large B-cell lymphoma. | Semantic Scholar
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B -cell Lymphoma. | Semantic Scholar
NIH study revises molecular classification for most common type of lymphoma | National Institutes of Health (NIH)
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study - eClinicalMedicine
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma
Ibrutinib in B-cell lymphoma: single fighter might be enough? | Cancer Cell International | Full Text
Preventing central nervous system spread in diffuse large B-cell lymphoma – novel approaches needed | Haematologica
Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma: Molecular Therapy - Oncolytics
Overall survival following Richter transformation on ibrutinib by line... | Download Scientific Diagram
Robyn's Stage 2E Relapsed Diffuse Large B-Cell Lymphoma Story - The Patient Story | For Cancer Patients & Caregivers
Frontiers | The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
AbbVie, Johnson & Johnson's Imbruvica comes up short in non-Hodgkin lymphoma trial | Fierce Pharma
The clinical picture of primary cutaneous diffuse large B-cell... | Download Scientific Diagram
Cureus | Systemic Aspergillosis: Radiological Findings in a Case With Diffuse Large B Cell Lymphoma Treated by Ibrutinib | Article
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma | Nature Medicine
Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma: Trends in Cancer
Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma | Acta Pharmacologica Sinica
Treatment resistance in diffuse large B-cell lymphoma | Leukemia
Cancers | Free Full-Text | Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study | Indian Journal of Hematology and Blood Transfusion
Frontiers | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas
Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma | Immunotherapy
Trial results show that younger lymphoma patients respond well to ibrutinib | Center for Cancer Research
Ibrutinib Boosts Survival in Younger Patients With Certain DLBCL Subtypes | MedPage Today
The key signaling pathways implicated in diffuse large B cell lymphoma... | Download Scientific Diagram
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
